The article draws a line: neural networks have learned to "understand" the language of DNA, RNA, and proteins just as LLMs understand English. We are moving from the manual design of molecules to autonomous drug discovery and the creation of full-scale virtual cells (in silico). The models are capable of predicting protein folding, the response of cellular systems to pathogens, and synthesizing new enzymes with specified properties. This review is a roadmap for venture capital for the next five years: the next trillion-dollar company will emerge precisely at the intersection of AI and biotech.
Source: Nature Biotechnology
BioTechScienceDNA/RNAVirtual CellsReview